Table 1.
Proposed indicators and targets
| Indicator | Target |
|---|---|
| Incidence* | |
| • Incidence (National) | Rate of decline commensurate with 2035 pre-elimination goals |
| • Incidence (on- and off-reserve First Nations) | |
| • Incidence (Inuit Nunangat) | |
| • Incidence (Atlantic Canada) | |
| • Incidence (Quebec) | |
| • Incidence (Ontario) | |
| • Incidence (Manitoba/Saskatchewan) | |
| • Incidence (Alberta/Northwest Territories) | |
| • Incidence (British Columbia/Yukon) | |
| Laboratory reporting | |
| • Turn-around time (NAAT) | 6 days (4 days specimen collection and delivery; 2 days detection) |
| • Turn-around time (Culture) | 25 days (4 days specimen collection and delivery; 21 days to grow)—78% |
| • Proportion HIV tested | 95% |
| • Proportion of culture-positive cases with DST | 100% |
| • Proportion of culture-positive cases with genotyping | 100% |
| for smear-positive pulmonary cases † | |
| • Sputum culture and CXR, end of initial phase | 100% |
| • Sputum culture and CXR, end of continuation phase | 100% |
| Case management and treatment | |
| • Proportion of pediatric cases (< 5 years) | < 5% |
| • CB cases/w no past hx TB started on a minimum of 3 drugs | 100% |
| • FB cases/w no past hx TB started on a minimum of 4 drugs | 100% |
| • Proportion with TB-related death of preceding years’ cases | < 5% |
| for smear-positive pulmonary cases | |
| • Starting treatment within 72 h of NAAT | 90% |
| • Complete treatment within 12 months | 95% |
| Contact investigations | |
| • Close contacts of smear-positive pulmonary cases: | |
| Proportion completely assessed < 5 years of age | 100% |
| Proportion completely assessed ≥ 5 years of age | 80% |
| • Close contacts with new positive TST/TST conversion: | |
| Proportion recommended TX LTBI < 5 years of age | 100% |
| Proportion recommended TX LTBI ≥ 5 years of age | 100% |
| • Close contacts recommended TX LTBI: | |
| Proportion who start treatment < 5 years of age | 100% |
| Proportion who start treatment ≥ 5 years of age | 80% |
| • Close contacts accepting TX LTBI: | |
| Proportion who complete treatment < 5 years of age | 100% |
| Proportion who complete treatment ≥ 5 years of age | 80% |
| IRCC referrals | |
| • Proportion who initiate examination within 30 days of notification | 100% |
| • Proportion completing examination within 90 days of notification | 100% |
| • Proportion of IRCC referrals recommended TX LTBI who accept | 90% |
| • Proportion of IRCC referrals accepting TX LTBI who complete | 90% |
| CTBRS reporting | |
| • Active TB case report form (last full year) complete | 100% |
| • Treatment outcome form (next to last full year) complete | 100% |
NAAT nucleic acid amplification test, DST drug susceptibility testing, CXR chest x-ray, CB Canadian-born, FB foreign-born, TX treatment, LTBI latent tuberculosis infection, IRCC Immigration Refugee and Citizenship Canada, CTBRS Canadian Tuberculosis Reporting System
*The proposed groupings take into account persons at risk, populations, existing organizational structures, and relationships
†The initial phase of treatment refers to an intensive three-four drug treatment regimen that lasts 2 months; the continuation phase lasts 4–7 months in fully susceptible cases and is usually a two-drug regimen